Merck &amp; Co Inc's&nbsp;experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on Tuesday (Nov 30).

The drug, developed along with Ridgeback Biotherapeutics, shows antiviral properties against coronavirus variants such as the Delta variant, Daria Hazuda, vice president of Merck's infectious diseases and vaccines division, said.

Hazuda's comments were part of a general presentation and not specific to the Omicron coronavirus variant.

READ ALSO:&nbsp;<a href="https://www.asiaone.com/world/moderna-ceo-says-vaccines-likely-less-effective-against-omicron-ft" target="_blank">Moderna CEO says vaccines likely less effective against Omicron: FT</a>

An experimental Covid-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on May 17, 2021. 

Covid-19 Omicron variant

COVID-19

coronavirus

medicine

drug

Reuters

Merck & Co Inc's experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on Tuesday (Nov 30). The drug, developed along with Ridgeback Biotherapeutics, shows antiviral properties against coronavirus variants such as the Delta variant, Daria Hazuda, vice president of Merck's infectious diseases and vaccines division, said. Hazuda's comments were part of...

Merck says its Covid-19 drug should be effective against any variant